Theralink Technologies stock analysis
Theralink Technologies (THER) Stock Price & Analysis
THER Stock Chart & Stats
- Day’s Range
- $0.01 - $0.02
- 52-Week Range
- $0.01 - $0.02
- Previous Close
- $0.01
- Volume
- N/A
- Average Volume (3M)
- 20.94M
- Market Cap
- $6,151
- Enterprise Value
- $19.38T
- Total Cash (Recent Filing)
- $998.28K
- Total Debt (Recent Filing)
- $19.76M
- Price to Earnings (P/E)
- 0.0
- Beta
- -15.85
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Theralink Technologies News
Theralink announces CAP accreditation for laboratory in Colorado
Earlier, Theralink Technologies announced that the company has received College of American Pathologists, or CAP, Accreditation for its Reverse Phase Protein Array laboratory in Golden, Colorado. The Accreditation Committee of
THER FAQ
What was Theralink Technologies’s price range in the past 12 months?
What is Theralink Technologies’s market cap?
When is Theralink Technologies’s upcoming earnings report date?
Is Theralink Technologies overvalued?
Does Theralink Technologies pay dividends?
What is Theralink Technologies’s EPS estimate?
How many shares outstanding does Theralink Technologies have?
Which hedge fund is a major shareholder of Theralink Technologies?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Theralink Technologies
Theralink Technologies, Inc., headquartered in Golden, Colorado, is a commercial-stage enterprise specializing in precision medicine and the generation of crucial molecular data. The company is dedicated to advancing and bringing to market innovative cancer immunotherapy products. Utilizing its proprietary platform, which focuses on phosphoprotein and protein biomarkers, alongside its sophisticated laboratory-developed test (LDT) technology, Theralink addresses diverse aspects of oncology and pharmaceutical research. Through their specialized Theralink Reverse Phase Protein Array assays, they provide highly accurate oncology data. This information enables the biopharmaceutical industry and clinical oncologists to more precisely predict which patients will respond to, or be resistant to, both FDA-approved and investigational drug treatments. Ultimately, Theralink's diagnostic assays deliver vital, actionable insights that benefit physicians, patients, and biopharmaceutical companies operating within the field of cancer care. The company adopted its current name, Theralink Technologies, Inc., in September 2020, having previously operated as OncBioMune Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael I. Ruxin
- Employees
- 16
- Website
- theralink.com
- Address
- 15000 West 6th Avenue, Golden, CO, 80401, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 5 |
| Technical Analysis | 2 | 3 | 1 |
| Moving Averages | 2 | 2 | 4 |







